DE3711724C2 - - Google Patents
Info
- Publication number
- DE3711724C2 DE3711724C2 DE3711724A DE3711724A DE3711724C2 DE 3711724 C2 DE3711724 C2 DE 3711724C2 DE 3711724 A DE3711724 A DE 3711724A DE 3711724 A DE3711724 A DE 3711724A DE 3711724 C2 DE3711724 C2 DE 3711724C2
- Authority
- DE
- Germany
- Prior art keywords
- liposomes
- genetic information
- membrane
- substance
- receptors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000002502 liposome Substances 0.000 claims description 39
- 241000700605 Viruses Species 0.000 claims description 28
- 230000002068 genetic effect Effects 0.000 claims description 22
- 239000012528 membrane Substances 0.000 claims description 21
- 239000000126 substance Substances 0.000 claims description 15
- 230000003612 virological effect Effects 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 10
- 108090000790 Enzymes Proteins 0.000 claims description 9
- 102000004190 Enzymes Human genes 0.000 claims description 9
- 239000003599 detergent Substances 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 230000035699 permeability Effects 0.000 claims description 6
- 210000000170 cell membrane Anatomy 0.000 claims description 5
- 230000000593 degrading effect Effects 0.000 claims description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 claims description 2
- 238000010348 incorporation Methods 0.000 claims description 2
- 239000000787 lecithin Substances 0.000 claims description 2
- 229940067606 lecithin Drugs 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- 230000007928 solubilization Effects 0.000 claims description 2
- 238000005063 solubilization Methods 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 27
- 210000004379 membrane Anatomy 0.000 description 17
- 108020003175 receptors Proteins 0.000 description 13
- 102000005962 receptors Human genes 0.000 description 13
- 239000004480 active ingredient Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 3
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 238000001125 extrusion Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000002200 mouth mucosa Anatomy 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 102000006481 HIV Receptors Human genes 0.000 description 1
- 108010083930 HIV Receptors Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 101100144701 Mus musculus Drosha gene Proteins 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 102000018265 Virus Receptors Human genes 0.000 description 1
- 108010066342 Virus Receptors Proteins 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 230000036576 dermal application Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000007501 viral attachment Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19873711724 DE3711724A1 (de) | 1987-04-07 | 1987-04-07 | System zum einwirken auf, insbesondere zerstoeren von viren |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19873711724 DE3711724A1 (de) | 1987-04-07 | 1987-04-07 | System zum einwirken auf, insbesondere zerstoeren von viren |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3711724A1 DE3711724A1 (de) | 1988-10-20 |
| DE3711724C2 true DE3711724C2 (https=) | 1992-05-07 |
Family
ID=6325067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19873711724 Granted DE3711724A1 (de) | 1987-04-07 | 1987-04-07 | System zum einwirken auf, insbesondere zerstoeren von viren |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE3711724A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0432693A1 (en) * | 1989-12-11 | 1991-06-19 | Sumitomo Chemical Company, Limited | Liposomes cytotoxic to virus-infected cells |
| DE69218403T2 (de) * | 1991-01-07 | 1997-06-26 | Syngenix Ltd | Für endocytose geeignete teilchen |
| WO1993002709A1 (en) * | 1991-07-31 | 1993-02-18 | Microcarb Inc. | Receptor conjugates for targeting drugs and other agents |
| CA2153780C (en) * | 1993-01-15 | 2004-04-13 | Micro Vesicular Systems, Inc. | Method of inhibiting viral reproduction |
| WO1995032734A1 (en) * | 1994-05-26 | 1995-12-07 | Innogenetics N.V. | New methods and compounds for the selective modulation of antigen-specific t-cell responsiveness |
| ES2088752B1 (es) * | 1995-01-27 | 1997-03-01 | Palomino Munoz Juan Manuel | Liposomas especificos para la eliminaci0n de vih y celulas infectadas por el mismo. |
| WO1996022763A1 (es) * | 1995-01-27 | 1996-08-01 | PALOMINO MUÑOZ, Juan Manuel | Liposoma para la destruccion del vih y de las celulas infectadas por el mismo |
| EP0904066A4 (en) * | 1996-05-03 | 2002-04-24 | Roger S Cubicciotti | DRUG COMPOSITIONS AND METHOD FOR ADMINISTERING DRUGS USING SYNTHETIC RECEPTORS |
| EP0979655A1 (de) * | 1998-08-01 | 2000-02-16 | Boehringer Mannheim Gmbh | Mittel zur Behandlung von durch RNA-Viren, wie beispielsweise HIV verursachten Infenktionen |
| JP6209517B2 (ja) * | 2011-08-26 | 2017-10-04 | ベコイ ナノメディシンズ リミテッドＶｅｃｏｙ Ｎａｎｏｍｅｄｉｃｉｎｅｓ Ｌｔｄ． | 病原体を捕獲するための合成物および薬学的組成物 |
-
1987
- 1987-04-07 DE DE19873711724 patent/DE3711724A1/de active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| DE3711724A1 (de) | 1988-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3852221T2 (de) | Tierische Zelle mit darin eingeführtem antigenem Protein. | |
| DE69828517T2 (de) | Methode zur dns-isolierung. | |
| DE3711724C2 (https=) | ||
| DE2915082C2 (https=) | ||
| DE69633669T2 (de) | Verfahren zur zelltransfektion mit liposomal-verkapselten nukleinsäuren | |
| EP0156961B1 (de) | Verfahren zur Herstellung hochgereinigter, stromafreier, hepatitissicherer Human- und Tierhämoglobinlösungen | |
| DE2907303A1 (de) | Verfahren zur einkapselung biologisch aktiver substanzen | |
| EP1289642B1 (de) | Nanokapseln mit einer polyelektrolythülle | |
| EP0338971A1 (de) | Verfahren zur Herstellung von Liposomen und/oder biologischer Zellen, die Inhaltsstoffe eingeschlossen haben, sowie deren Verwendung | |
| DE2655801A1 (de) | Verfahren zur herstellung einer masse von in einer physiologischen loesung suspendierten beladenen zellen | |
| SE445423B (sv) | Forfarande for framstellning av en suspension av i fysiologisk losning suspenderade och med metotrexat eller 6-fluorouracil belastade blodceller samt magnetiska substanser | |
| DE2725696A1 (de) | Synthetisches liposom und verfahren zur herstellung | |
| EP0776194B1 (de) | Unilamellare liposomenzubereitungen mit hohem wirkstoffanteil | |
| JPS60184021A (ja) | グルタミン酸レセプタ−阻害物質 | |
| EP0971692A2 (de) | Spezifische magnetosomen, verfahren zu ihrer herstellung und ihre verwendung | |
| DE3026180A1 (de) | Verwendung von rifamycin sv und seinen salzen in form von praeparaten zur intraartikulaeren injektion bei der bekaempfung von rheumatoider arthritis | |
| DD209736A5 (de) | Verfahren zur herstellung zell- und geweberegenerierender stoffe | |
| DE69310844T3 (de) | Benutzeraktivierte, iontophoretische vorrichtung | |
| EP1796649A2 (de) | Nanotransportsystem mit dendritischer architektur | |
| DE2323981A1 (de) | Antikoagulansisolierung | |
| DE3815473C2 (https=) | ||
| DE19954843C2 (de) | Verfahren zur Verkapselung von Proteinen oder Peptiden in Liposomen, mit dem Verfahren hergestellte Liposomen und deren Verwendung | |
| DE2650502B2 (de) | Herstellung von Iiposomen welche Arzneistoffe enthalten | |
| EP3558336A1 (de) | D-enantiomere peptide zur therapie von chronischem und neuropathetischem schmerz | |
| DE2822731A1 (de) | Vaccine zur immuntherapie neoplastischer erkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |